PortfoliosLab logo
Psychemedics Corporation (PMD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US7443752057

CUSIP

744375205

IPO Date

Feb 17, 1994

Highlights

Market Cap

$15.74M

EPS (TTM)

-$0.51

Total Revenue (TTM)

$9.90M

Gross Profit (TTM)

$3.59M

EBITDA (TTM)

-$830.00K

Year Range

$1.63 - $3.25

Target Price

$32.00

Short %

0.31%

Short Ratio

0.79

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Psychemedics Corporation

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


PMD

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of PMD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20248.11%-1.11%-7.41%-11.77%-7.16%0.83%-5.80%0.89%0.43%0.87%-0.21%14.84%-9.80%
202314.18%0.54%-5.54%3.62%-11.62%-3.80%8.77%-14.92%-5.92%-38.29%4.49%15.63%-37.99%
20221.85%-4.34%0.88%-10.00%2.90%0.32%-0.32%5.85%-2.57%0.31%-11.90%-12.88%-27.73%
202133.59%2.94%-11.43%7.26%-0.75%5.45%5.03%12.04%2.56%-1.07%-5.66%-9.82%38.90%
20203.82%-5.08%-31.56%-0.83%-3.33%-4.31%-16.94%-1.73%-2.65%-14.51%14.59%17.82%-43.26%
201914.43%7.71%-27.41%-18.10%-9.25%-1.56%-10.70%-11.54%16.79%5.71%-3.49%0.33%-38.19%
2018-2.68%5.95%1.48%-1.40%-4.40%-3.61%8.60%-6.71%-2.69%-6.96%0.92%-9.21%-20.09%
2017-23.54%13.39%-5.65%-4.89%9.33%20.59%2.45%-16.69%-12.82%-5.05%6.20%11.56%-14.14%
2016-7.40%36.62%8.52%4.80%-2.46%-1.22%34.50%10.55%-2.22%18.47%7.15%-1.24%152.68%
2015-1.25%10.70%1.10%-6.51%-6.46%3.20%-18.95%-6.78%-9.13%3.58%12.92%-12.59%-29.99%
20144.22%17.30%-3.82%-8.00%-2.41%-7.03%-0.92%2.96%-0.91%1.55%5.95%0.46%7.25%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of PMD is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of PMD is 4444
Overall Rank
The Sharpe Ratio Rank of PMD is 4242
Sharpe Ratio Rank
The Sortino Ratio Rank of PMD is 4545
Sortino Ratio Rank
The Omega Ratio Rank of PMD is 4646
Omega Ratio Rank
The Calmar Ratio Rank of PMD is 4444
Calmar Ratio Rank
The Martin Ratio Rank of PMD is 4444
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Psychemedics Corporation (PMD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Psychemedics Corporation. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History

Psychemedics Corporation provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%2.00%4.00%6.00%8.00%$0.00$0.20$0.40$0.60$0.802014201520162017201820192020202120222023
Dividends
Dividend Yield
PeriodTTM2023202220212020201920182017201620152014
Dividend$0.00$0.14$0.21$0.05$0.18$0.72$0.69$0.60$0.60$0.60$0.60

Dividend yield

0.00%4.73%4.28%0.71%3.54%7.87%4.35%2.92%2.43%5.92%3.96%

Monthly Dividends

The table displays the monthly dividend distributions for Psychemedics Corporation. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2023$0.00$0.00$0.07$0.00$0.07$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.14
2022$0.00$0.00$0.00$0.00$0.07$0.00$0.00$0.07$0.00$0.00$0.00$0.07$0.21
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.05$0.05
2020$0.00$0.18$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.18
2019$0.00$0.00$0.18$0.00$0.18$0.00$0.00$0.18$0.00$0.00$0.18$0.00$0.72
2018$0.00$0.00$0.15$0.00$0.18$0.00$0.00$0.18$0.00$0.00$0.18$0.00$0.69
2017$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.60
2016$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.60
2015$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.60
2014$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.00$0.15$0.00$0.60

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Psychemedics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Psychemedics Corporation was 92.56%, occurring on Aug 8, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.56%Jul 12, 20171781Aug 8, 2024
-84.19%Jul 14, 19953337Mar 10, 20091240Feb 13, 20144577
-53.37%Feb 18, 2014491Jan 28, 2016125Jul 27, 2016616
-38.46%Aug 23, 1994142Mar 15, 199582Jul 12, 1995224
-29.4%Jan 27, 201765May 1, 201749Jul 11, 2017114
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Psychemedics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Psychemedics Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 62.5% positive surprise.


-0.40-0.30-0.20-0.100.000.10AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-0.09
Actual
Estimate

Valuation

The Valuation section provides an overview of how Psychemedics Corporation is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for PMD compared to other companies in the Diagnostics & Research industry. PMD currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for PMD relative to other companies in the Diagnostics & Research industry. Currently, PMD has a P/S ratio of 0.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for PMD in comparison with other companies in the Diagnostics & Research industry. Currently, PMD has a P/B value of 2.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items